期刊文献+

重组嵌合毒素Dsg3EC_(1-2)PE40对寻常型天疱疮患者T、B淋巴细胞的影响 被引量:1

Effects of Recombinant Chimeric Toxin Dsg3EC_(1-2)PE40 on T and B Lymphocytes from Pemphigus Vulgaris
原文传递
导出
摘要 目的探讨重组嵌合毒素Dsg3EC1-2PE40对寻常型天疱疮患者外周血淋巴细胞的影响.方法对重组嵌合毒素Dsg3EC1-2PE40进行表达,并分离纯化;分别以不同浓度重组嵌合毒素作用于寻常型天疱疮患者外周血淋巴细胞,通过ELISPOT法、MTT比色试验及3H-TdR掺入试验来观察重组嵌合毒素对T、B淋巴细胞的影响.结果纯化后的重组嵌合毒素纯度达80%以上,它能够特异性与天疱疮抗体IgG结合,而与正常人IgG不结合.重组嵌合毒素可使寻常型天疱疮外周血产生抗体的B细胞数量减少约40%左右;在重组嵌合毒素作用下,T细胞的增殖、代谢较重组Dsg3EC1-2明显降低,两者间差异有统计学意义(P<0.01).结论重组嵌合毒素Dsg3EC1-2PE40可以抑制寻常型天疱疮外周血B细胞的抗体产生作用,对寻常型天疱疮外周血T细胞具有明显的抑制或杀伤作用. Objective To study the effects of recombinant chimeric toxin Dsg3EC1-2PE40 on T and B cells from PV patients. Methods The recombinant protein Dsg3EC1-2PE40 was expressed on BL21TrxB (DE3) cells, then identified and purified. ELISPOT assay was used to detect and quantitate autoantibody-producing B cells in different concentrations of recombinant chimeric toxin, and MTT assay and 3H-TdR assay to observe the metabolism and proliferation of T cells from PV patients in vitro. Results The purity of expressed protein Dsg3EC1-2PE40 was up to 80%. The number of anti-Dsg3 antibody-producing B cells in PBMC from PV patients decreased by 40% with treatment of Dsg3EC1-2PE40, which was significantly lower (P〈0.01 ) than those with treatment of Dsg3EC1-2. Compared with Dsg3EC1-2, Dsg3EC1-2PE40 markedly inhibited the metabolism and proliferation of T cells from PV patients (P〈0.01 ). Conclusions Recombinant chimeric toxin Dsg3EC1-2PE40 can reduce the number of anti-Dsg3 antibody-producing B cells and inhibit or kill T cells from PV patients in vitro.
出处 《中华皮肤科杂志》 CAS CSCD 北大核心 2005年第9期536-539,共4页 Chinese Journal of Dermatology
  • 相关文献

参考文献7

  • 1赖春宁,黎燕,齐春会,孙瑛勋,沈倍奋.酶联免疫斑点方法改进及应用[J].上海免疫学杂志,2001,21(6):355-356. 被引量:4
  • 2Czerkinsky CC, Nilsson LA, Nygren H, et al. A solid-phase enzymelinked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. J Immunol Methods, 1983, 65: 109-121.
  • 3Siegall CB, Chaudhary VK, FitzGerald DJ, et al. Functional analysis of domains Ⅱ, Ib, and Ⅲ of Pseudomonas exotoxin. J Biol Chem,1989, 264: 14256-14261.
  • 4Pastan I, Chaudhary V, FitzGerald DJ. Recombinant toxins as novel therapeutic agents. Annu Rev Biochem, 1992, 61: 331-354.
  • 5Proby CM, Ota T, Suzuki H, et al. Development of chimeric molecules for recognition and targeting of antigen-specific B cells in pemphigus vulgaris. Br J Dermatol, 2000, 142: 321-330.
  • 6Chaudhary VK, Xu YH, FitzGerald D, et al. Role of domain Ⅱ of Pseudomonas exotoxin in the secretion of proteins into the periplasm and medium by Escherichia coli. Proc Natl Acad Sci U S A, 1988,85: 2939-2943.
  • 7Nishifuji K, Amagai M, Kuwana M, et al. Detection of antigen-spe-cific B ceils in patients with pemphigus vulgaris by enzyme-linked immunospot assay: requirement of T cell collaboration for autoantibody production. J Invest Dermatol, 2000, 114: 88-94.

二级参考文献2

共引文献3

同被引文献11

  • 1黄文广,罗威,黄汉菊.靶向DF3的白喉毒素A链基因对乳腺癌细胞的杀伤作用[J].中华实验外科杂志,2007,24(1):15-17. 被引量:4
  • 2Jang YJ, Stollar BD. Anti-DNA antibodies: aspects of structure and pathogenicity[J].Cell Mol Life Sci ,2003,60(2):309.
  • 3Migliorini P ,Pratesi F ,Bongiorni F,et al.The targets of nephrltogenic antibodies in systemicautoimmune disorders[J].Autoimmunity Reviews, 2002,1(3):168.
  • 4Criscione LG,Pisetsky DS. B lymphocytes and systemic lupus erythematosus[J].Curr Rheumatol Rep,2003,5(4) :264.
  • 5Mageed RA ,Prud'homme GJ. Immunopathology and the gene therapy of lupus[J].Gene Ther, 2003,10( 10):861.
  • 6Fan GC ,Singh RR.Vaccinatlon with mlnigenes encoding V(H)-derived major histocompatibility complex class Ⅰ-binding epitopes activates cytotoxic T cells that ablate autoantibody-preducing B cells and inhibit lupus[J].J Exp Med ,2002,196(6):731.
  • 7Mohan C ,Shi Y ,Laman JD,et al. Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis[J]. J Immunol, 1995,154(3) : 1470.
  • 8Sfikakis PP,Via CS. Expression of CD28 ,CTLA4 ,CD80, and CD86 molecules in patients with autoimmune rheumatic diseases:implieations for immunotherapy[J].Clin Immunol Immunopathol, 1997,83(3) :195.
  • 9Fan GC ,Singh RR.Vaccination with minigenes encoding V(H)-derived major histocompatibility complex class Ⅰ-binding epitopes activates cytotoxic T cells that ablate autoantibedy-producing B cells and inhibit lupus[J].J Exp Med ,2002,196(6):731.
  • 10Hong NM, MasukoHK,Sasakawa H ,et al. Amelioration of lymphoid hyperplasia and hypergammaglobulinemia in lupus2prone mice (gld) by Fas-ligand gene transfer[J].J Autoimmun, 1998,11(4):301.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部